Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec:113:154395.
doi: 10.1016/j.metabol.2020.154395. Epub 2020 Oct 12.

ApoCIII: A multifaceted protein in cardiometabolic disease

Laura D'Erasmo  1 , Alessia Di Costanzo  2 , Antonio Gallo  3 , Eric Bruckert  3 , Marcello Arca  4
Affiliations
Review

ApoCIII: A multifaceted protein in cardiometabolic disease

Laura D'Erasmo et al. Metabolism. 2020 Dec.

Abstract

ApoCIII has a well-recognized role in triglyceride-rich lipoproteins metabolism. A considerable amount of data has clearly highlighted that high levels of ApoCIII lead to hypertriglyceridemia and, thereby, may influence the risk of cardiovascular disease. However, recent findings indicate that ApoCIII might also act beyond lipid metabolism. Indeed, ApoCIII has been implicated in other physiological processes such as glucose homeostasis, monocyte adhesion, activation of inflammatory pathways, and modulation of the coagulation cascade. As the inhibition of ApoCIII is emerging as a new promising therapeutic strategy, the complete understanding of multifaceted pathophysiological role of this apoprotein may be relevant. Therefore, the purpose of this work is to review available evidences not only related to genetics and biochemistry of ApoCIII, but also highlighting the role of this apoprotein in triglyceride and glucose metabolism, in the inflammatory process and coagulation cascade as well as in cardiovascular disease.

Keywords: APOC3 gene; APOC3 gene expression; ApoCIII protein; Cardiovascular disease risk; Therapeutic target; Triglycerides; Triglycerides (TG)-rich lipoproteins (TRL).

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest LD has received personal fees for public speaking, consultancy or grant support from Amryt Pharmaceuticals, Akcea Therapeutics, Pfizer, Amgen and Sanofi; MA has received research grant support from Amryth Pharmaceutical, Amgen, IONIS, Akcea Therapeutics, Pfizer and Sanofi; has served as a consultant for Amgen, Aegerion, Akcea Therapeutics, Regeneron, Sanofi and Alfasigma and received lecturing fees from Amgen, Amryth Pharmaceutical, Pfizer, Sanofi and AlfaSigma; AG has received personal fees for public speaking or consultancy support from Akcea Therapeutics, AMGEN, MSD, Mylan, Novartis, Sanofi and Regeneron, Unilever; EB has received honoraria from AMGEN, MSD, Sanofi and Regeneron, Unilever, Danone, Aegerion, Chiesi, Rottapharm-MEDA, Servier, Ionis-pharmaceuticals, AKCEA and MYLAN. ADC does not have any potential conflict of interest.

MeSH terms